Ligand or GMP-140 selectin and methods of use thereof
US5929036A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Jun 6, 1995 |
| Grant date | Jul 27, 1999 |
| Priority date | — |
| Expiry date | Jun 6, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Fucosylated sialyated lactosaminoglycan structures that bind to GMP-140 have been discovered. The structure is created by expression of .alpha.(1,3) fucosyltransferases capable of modifying acceptors containing .alpha.(2,3) sialic acid-substituted lactosaminoglycans. Le.sup.x, Gal.beta.1,4(Fuc.alpha.1,3) GlcNAc.beta.1-R (where R is a protein or other carbohydrate structure), a common trisaccharide structure on myeloid cells but not on lymphocytes or erythroid cells, forms the core of this sialyated structure. The actual structure may be sialyl Le.sup.x, difucosyl sialyl Le.sup.x, a longer polyfucosylated polyactosaminoglycan, or a related variant. Several of these structures may bind to GMP-140 with various degrees of affinity. The carbohydrate structures, including sialyl Le.sup.x, difucosyl sialyl Le.sup.x, or a longer polyfucosylated polyactosaminoglycan variant, produced synthetically or expressed in genetically engineered cells, are useful as diagnostics and, in combination with a suitable pharmaceutical carrier, for clinical applications in the modulation or inhibition of coagulation processes or inflammatory processes. Antibodies to these structures can also be used as diagn…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.